SCHEMBL23068652

SCHEMBL23068652

CNc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCN(C(C)=O)CC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 5/20 0.53
CDK2 P24941 5/20 0.53
CCNT1 O60563 2/20 0.53
CCNA2 P20248 2/20 0.53
AURKA O14965 3/20 0.52
CDK7 P50613 3/20 0.52
AURKB Q96GD4 3/20 0.52
CDK1 P06493 3/20 0.52
WEE1 P30291 2/20 0.52
ALK Q9UM73 2/20 0.52
CDK4 P11802 2/20 0.52
CDK8 P49336 8/20 0.51
CCNC P24863 5/20 0.51
RET P07949 3/20 0.51
ABL1 P00519 4/20 0.49
NTRK1 P04629 2/20 0.49
NTRK2 Q16620 2/20 0.49
TEK Q02763 1/20 0.49
MAP4K2 Q12851 2/20 0.49
MAPK14 Q16539 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629215 1.00 CDK9 (0.53) CDK9CDK2CCNT1CCNA2AURKA
SCHEMBL23068622 0.93 CDK8 (0.54) CDK9CDK2CCNT1CCNA2AURKA
SCHEMBL29629236 0.93 CDK8 (0.54) CDK9CDK2CCNT1CCNA2AURKA
SCHEMBL29629238 0.93 RET (0.60) CDK9CDK2AURKACDK7AURKB
SCHEMBL23068646 0.93 CDK8 (0.59) CDK2CDK1CDK8CCNCRET
SCHEMBL29629218 0.93 CDK8 (0.59) CDK2CDK1CDK8CCNCRET
SCHEMBL23068681 0.93 RET (0.60) CDK9CDK2AURKACDK7AURKB
SCHEMBL23068637 0.92 CDK8 (0.58) CDK9CDK2CCNT1CCNA2AURKA
SCHEMBL29629205 0.92 CDK8 (0.58) CDK9CDK2CCNT1CCNA2AURKA
SCHEMBL23068640 0.91 CDK8 (0.51) CDK9CDK2AURKACDK7AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN claimed
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP disclosed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 CDK9 3/4885CDK2 8/4885CCNT1 75/4885
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK9 3/4885CDK2 8/4885CCNT1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.